• Q-VD-OPh: Reliable Caspase Inhibition

  2026-09-18

  Learn how Q-VD-OPh (SKU A1901) can clarify caspase-dependent cell death, support post-cryopreservation viability studies, and improve interpretation of apoptosis assays. This scenario-based guide covers experimental controls, solvent handling, data interpretation, and practical product selection.

• AY 9944 Dihydrochloride: Causal DHCR7 Assays

  2026-09-18

  AY 9944 dihydrochloride is a selective DHCR7 inhibitor for experimentally shifting sterol balance from cholesterol toward 7-dehydrocholesterol. This article develops a causal assay framework that connects biochemical inhibition with immune, membrane-raft, and emerging antiviral evidence while distinguishing chemical perturbation from permanent gene disruption.

• Dextromethorphan Hydrobromide for Neuroprotection

  2026-09-17

  Build more informative neuroprotection experiments with Dextromethorphan hydrobromide, an NMDA receptor antagonist tool that also affects voltage-operated ion currents. This guide connects concentration-response design, electrophysiology, excitotoxicity inhibition, and translational model selection while separating product facts from workflow starting points.

• Ciprofloxacin–RSL3 Ferroptosis via STING1–CAV2

  2026-09-17

  The reference study shows that ciprofloxacin can either suppress or enhance ferroptosis depending on the initiating stimulus: it potentiates RSL3-induced death by driving mitochondrial Zn2+ accumulation through a STING1–CAV2 pathway. Its findings connect topoisomerase 2β inhibition, mitochondrial DNA stress, zinc transport, and mitochondrial reactive oxygen species, while also defining practical considerations for cell viability measurement in ferroptosis experiments.

• Malate as a Flux and Redox Probe

  2026-09-16

  Malate and (S)-2-hydroxysuccinic acid provide a versatile way to interrogate TCA-cycle carbon flow, mitochondrial redox balance, and metabolic-immune signaling. This article translates recent cholangiocarcinoma findings into a practical assay framework that distinguishes flux effects from redox artifacts.

• TG003: From Splicing Control to CLK2 Translation

  2026-09-16

  TG003 is a research-grade Cdc2-like kinase inhibitor that connects reversible control of serine/arginine-rich protein phosphorylation with translational questions in alternative splicing, exon-skipping therapy, and CLK2-associated platinum resistance.

• AO/PI Cell Counting in Diabetic Nephropathy

  2026-09-15

  Learn how AO/PI Staining Solution and orthogonal viability measurements can strengthen mechanistic studies of diabetic nephropathy, including research on phillygenin, inflammation, and apoptosis.

• L. reuteri FN041 Reshapes Colitis-Associated Microbiota

  2026-09-15

  This mouse study shows that human milk-derived Limosilactobacillus reuteri FN041 alleviates DSS-induced colitis alongside improvements in intestinal barrier markers, inflammatory responses, gut microbiota, and cecal metabolites. Its multi-omics design supports a microbiota–metabolite mechanism, while the findings remain preclinical and require validation in controlled translational studies.

• NF 449: Designing Better P2X1 Platelet Assays

  2026-09-14

  NF 449 is a highly selective purinergic receptor antagonist for separating P2X1 signaling from broader platelet purinergic biology. This guide translates recombinant-receptor pharmacology into practical assay design, controls, storage decisions, and interpretation for platelet activation and thrombosis research.

• U0126 for MEK1/2 Mechanistic Assays

  2026-09-14

  U0126 converts substrate-stiffness experiments from pathway correlation into testable MEK1/2 causality. This practical guide connects PDMS mechanobiology, time-resolved ERK readouts, mineralization assays, and troubleshooting for reproducible MAPK/ERK pathway inhibition.

• Aβ42 Peptide: Ion Channels and Microglial Clearance

  2026-09-13

  A mechanistic guide to using human Amyloid β-Peptide (1-42) for integrated neurotoxicity, ion-channel, and microglial clearance studies in translational Alzheimer’s disease research.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma

  2026-09-12

  Shiota and colleagues developed a dCAS9-based reporter screen that identified structurally diverse HDAC inhibitors as suppressors of NUT-driven transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomains, oncogene repression, cellular differentiation, and tumor-growth control, providing a mechanistic framework for therapeutic investigation in NUT carcinoma.

• SCP4, H3T3 Dephosphorylation, and Chromosome Stability

  2026-09-11

  The reference study identifies SCP4 as a nuclear phosphatase that removes the mitotic H3T3 mark, refining the regulatory balance that positions the chromosomal passenger complex on mitotic chromosomes. Cellular and mouse-zygote experiments connect disrupted SCP4 activity with chromosome missegregation, aneuploidy, and early cleavage defects, establishing SCP4 as an important regulator of mitotic fidelity.

• Purmorphamine for Smo Signaling Workflows

  2026-09-11

  Purmorphamine is a practical Smoothened agonist for connecting Hedgehog pathway activation with osteogenic, neural, and sensory readouts. This guide translates product specifications and honeybee Smo findings into dose-selection, assay-design, and troubleshooting decisions.

• Carbapenemase Gene Transmission in Guangdong CREC

  2026-09-10

  Chen et al. integrated gene localization, antimicrobial susceptibility, conjugation, mobile-element analysis, and ERIC-PCR typing to characterize carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. The study shows that blaNDM-1 was frequently plasmid-associated and transferable, linking multidrug resistance with substantial potential for horizontal and clonal dissemination.

581 records 6/39 page Previous Next First page 上5页 678910 下5页 Last page